These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11364691)

  • 21. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. T-20 salvage results hold up at 48 weeks.
    Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):77-8. PubMed ID: 14666913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T-20 continues to look promising.
    AIDS Patient Care STDS; 1999 Dec; 13(12):753. PubMed ID: 10743540
    [No Abstract]   [Full Text] [Related]  

  • 23. [Enfuvirtide, the first representative of a new class of drugs for the treatment of HIV infection : HIV fusion inhibitors].
    Koopmans PP
    Ned Tijdschr Geneeskd; 2003 Sep; 147(36):1726-9. PubMed ID: 14520797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [HIV infections: further options for combination therapy].
    Hildegard K
    Dtsch Med Wochenschr; 2003 Jul; 128(28-29):1523. PubMed ID: 12899165
    [No Abstract]   [Full Text] [Related]  

  • 25. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients.
    Viard JP; Fagard C; Chaix ML; Rouzioux C; Bouteloup V; Bentata M; de Verdière NC; Pahlavan G; Weiss L; Lévy Y; Chêne G;
    AIDS; 2009 Jul; 23(11):1383-8. PubMed ID: 19461505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three new drugs approved by FDA.
    Hoyt G
    Surviv News (Atlanta Ga); 2003; ():13, 20. PubMed ID: 14696579
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-HIV drug updates--three drugs on the near horizon.
    Proj Inf Perspect; 2003 Jan; (35):4-7. PubMed ID: 12647672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James.
    Grossman H
    AIDS Treat News; 2002 Sep; (383):2-7. PubMed ID: 12765126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
    Poveda E; Rodés B; Labernardière JL; Benito JM; Toro C; González-Lahoz J; Faudon JL; Clavel F; Schapiro J; Soriano V
    J Med Virol; 2004 Sep; 74(1):21-8. PubMed ID: 15258964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.
    Kilby JM; Hopkins S; Venetta TM; DiMassimo B; Cloud GA; Lee JY; Alldredge L; Hunter E; Lambert D; Bolognesi D; Matthews T; Johnson MR; Nowak MA; Shaw GM; Saag MS
    Nat Med; 1998 Nov; 4(11):1302-7. PubMed ID: 9809555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-20 and adefovir for salvage therapy -- expect no miracles.
    Gilden D
    GMHC Treat Issues; 1998 Apr; 12(4):6-7. PubMed ID: 11365400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enfuvirtide beneficial in experienced patients.
    AIDS Patient Care STDS; 2004 Jan; 18(1):57. PubMed ID: 15080095
    [No Abstract]   [Full Text] [Related]  

  • 34. T-20: first of a new class of anti-HIV drugs.
    Hanna L
    BETA; 1999 Jan; 12(1):7-8. PubMed ID: 11367243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living.
    Cohen CJ; Dusek A; Green J; Johns EL; Nelson E; Recny MA
    AIDS Patient Care STDS; 2002 Jul; 16(7):327-35. PubMed ID: 12194730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combined treatment with fusion inhibitor. HIV-1 viruses under control longer].
    MMW Fortschr Med; 2004 Apr; 146(15):68. PubMed ID: 15373030
    [No Abstract]   [Full Text] [Related]  

  • 37. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
    Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
    [No Abstract]   [Full Text] [Related]  

  • 38. New-Fill on "hold" and open-label for T-20.
    Berger DS
    Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532
    [No Abstract]   [Full Text] [Related]  

  • 39. First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases.
    Bourgarit A; Lascoux C; Palmer P; Tuleja E; Pintado C; Farge D; Sereni D
    AIDS; 2006 Feb; 20(3):471-3. PubMed ID: 16439888
    [No Abstract]   [Full Text] [Related]  

  • 40. Fusion inhibitors: T-20 and T-1249.
    TreatmentUpdate; 2001; 12(12):2-3. PubMed ID: 11570088
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.